Home
About
FAQ
History (25)
Relation of the CHA2DS2-VASc Score to Risk of Thrombotic and Embolic Stroke in Community-Dwelling Individuals Without Atrial Fibrillation (From The Atherosclerosis Risk in Communities [ARIC] Study).
Do pretransplant C-peptide levels influence outcomes in simultaneous kidney-pancreas transplantation?
Management of Residual Psoriasis in Patients on Biologic Treatment
Party behaviors and characteristics and serial drunkenness among college students.
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
See All 25 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother. 2020 04; 54(4):380-387.
View in:
PubMed
subject areas
Antibodies, Monoclonal
Biological Products
Humans
Interleukin-23 Subunit p19
Psoriasis
Severity of Illness Index
Treatment Outcome
United States
United States Food and Drug Administration
authors with profiles
Steven R. Feldman MD, PhD